Integrative principles of adaptive medical immunology in the treatment of secondary immunodeficiency: relevance of interdisciplinary interactions

In 2023, we created a new scientific direction — Adaptive medical immunology, which continues to develop successfully at the present time. The close relationship between the normally functioning nervous, endocrine, and immune systems was convincingly demonstrated in experimental studies back in the 80s and 90s of the 20th century. Later, in the 15—20s of the 21st century, the attention of scientists began to attract the importance of normalizing dysregulatory disorders within the neuroimmunoendocrine interface in clinical practice. We have shown that secondary immunodeficiency in both children and adults is often associated with various diseases of the nervous system and endocrinopathies. Today, we have convincingly shown that secondary immunodeficiency, as a disease of the immune system, is an independent nosological form, which requires certain solutions in the field of creating technologies for diagnostics, prevention, treatment and rehabilitation of the immune system. For more than 30 years, we have developed various methods to restore the immune system in patients with secondary immunodeficiency. These methods include immunomodulatory therapy or targeted immunomodulatory therapy to treat secondary immunodeficiency. On the other hand, when secondary immunodeficiency is combined with pathology of the nervous and endocrine systems, an interdisciplinary approach is needed to achieve full restoration of immune system function. The application of the principles of adaptive medical immunology, consisting in a personalized interdisciplinary approach, makes it possible to achieve positive clinical and immunological effectiveness by normalizing the interface of the neuroimmunoendocrine complex and restoring the adaptive capabilities of the immune system, primarily in the fight against pathogens, which significantly improves the health and quality of life of “problematic”, immunocompromised multimorbid patients.